Characterization of Anti-PEG Antibodies to Support Clinical Development of GLM101, a Liposome-Based Therapeutic Candidate for PMM2-CDG
Time: 10:00 am
day: Day One
Details:
- Clinical feedback on liposome product given to patients chronically
- Optimal strategy on collecting immunogenicity data
- Exploring the impact of PEG antibodies on clinical performance
